



Reference list

CliniMACS® CD34 Reagent System (HUD)

Comparative Outcome of Donor Graft CD34+ Selection and Immune Suppressive Therapy as Graft-versus-Host Disease Prophylaxis for Patients with Acute Myeloid Leukemia in Complete Remission Undergoing HLA-Matched Sibling Allogeneic Hematopoietic Cell Transplantation.

Pasquini MC, Devine S, Medizabal A, Baden LR, Wingard JR, Lazarus HM, Appelbaum FR, Keever-Taylor CA, Horowitz MM, Carter S, O'Reilly RJ, Soiffer RJ.

J Clin Oncol. 2012, 30(26):3194-201.

doi: 10.1200/JCO.2012.41.7071.

Characteristics of CliniMACS® System CD34-Enriched T Cell-Depleted Grafts in a Multicenter Trial for Acute Myeloid Leukemia - Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0303.

Keever-Taylor CA, Devine SM, Soiffer RJ, Mendizabal A, Carter S, Pasquini MC, Hari PN, Stein A, Lazarus HM, Linker C, Goldstein SC, Stadtmauer EA, O'Reilly RJ.

Biol Blood Marrow Tr. 2012 18(5):690-7.

doi: 10.1016/j.bbmt.2011.08.017.

Low Risk of Chronic Graft-versus-Host Disease and Relapse Associated with T Cell-Depleted Peripheral Blood Stem Cell Transplantation for Acute Myelogenous Leukemia in First Remission: Results of the Blood and Marrow Transplant Clinical Trials Network Protocol 0303.

Devine SM, Carter S, Soiffer RJ, Pasquini MC, Hari PN, Stein A, Lazarus HM, Linker C, Stadtmauer EA, Alyea EP 3rd, Keever-Taylor CA, O'Reilly RJ.

Biol Blood Marrow Tr. 2011, 17(9):1343-51.

doi: 10.1016/j.bbmt.2011.02.002.

Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission: Systematic Review and Meta-Analysis of Prospective Clinical Trials.

Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, Wadleigh M, DeAngelo DJ, Stone RM, Sakamaki H, Appelbaum FR, Döhner H, Antin JH, Soiffer RJ, Cutler C.

JAMA. 2009, 301(22):2349-61.

doi: 10.1001/jama.2009.813.



Miltenyi Biotec provides products and services worldwide. Visit www.miltenyibiotec.com/local to find your nearest Miltenyi Biotec contact.

The CliniMACS® System components including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer are manufactured and controlled under an ISO 13485 certified quality system. In the EU, the CliniMACS System components are available as CE-marked medical devices. In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Set TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved; all other products of the CliniMACS product line are available for use only under an approved Investigational New Drug (IND) application or Investigational Device Exemption (IDE). In the US, the components of the CliniMACS Prodigy System are for research use only and not for human therapeutic or diagnostic use. CliniMACS MicroBeads are for research use only and not for human therapeutic or diagnostic use. Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research only and not for therapeutic or diagnostic use.

CliniMACS, CliniMACS Prodigy, and MACS are registered trademarks of Miltenyi Biotec.

Copyright© 2018 Miltenyi Biotec GmbH. All rights reserved.